University of Kentucky Joins The TriNetX Network To Revolutionize Clinical Trial Design To Enhance And Accelerate The Development Of New Drugs
CAMBRIDGE, Mass., June 8, 2016 /PRNewswire/ -- TriNetX, a leader in international clinical research networks, announced today that the University of Kentucky (UK) signed a membership agreement to join the TriNetX network to optimize clinical trial design and advance clinical research for UK programs.
Pharmaceutical researchers will gain access to UK's clinical data in real time through TriNetX's proprietary network of healthcare institutions representing over 37 million patients in the US and Europe to support clinical study and protocol design, site selection, and patient recruitment across a range of therapeutic areas and development stages.
UK will leverage the TriNetX network to drive more industry-sponsored clinical trials into its organization, enable UK researchers to discover patients for investigator-initiated studies, and collaborate with other provider research organizations.
Users of the TriNetX system can analyze patient populations with search criteria across multiple longitudinal data points, and TriNetX's advanced analytics modules provide intelligence on which criteria have the most impact as well as the rate at which new patients present. Each data point in the TriNetX system can be traced to healthcare providers who have the ability to identify individual patients, allowing clinical researchers to develop virtual patient cohorts that can be recapitulated in real world clinical trial settings. Data in the TriNetX system is fully de-identified to the user.
"The University of Kentucky is one of only 23 institutions in the nation with the 'trifecta' of a cancer center designated by the National Cancer Institute, an Alzheimer's Disease Center funded by the National Institute on Aging, and a Clinical and Translational Science Award funded by the National Center for Advancing Translational Sciences," said Philip A. Kern, MD, director of the UK Center for Clinical and Translational Science. "Our institution, which encompasses the full range of liberal arts, medical and professional programs, including a top five College of Pharmacy, is committed to advancing health discoveries through innovative partnerships like our work with TriNetX."
"The University of Kentucky brings cutting-edge research and treatment options to a complex patient population in a state with some of the highest incidence rates of cancer, heart disease, and smoking," said Gadi Lachman, CEO, TriNetX. "The University of Kentucky is poised to be a strategic research partner for leading pharmaceutical companies, contract research organizations, and peer provider organizations who are collaborating through the TriNetX network to improve clinical research and patient care."
TriNetX is a worldwide clinical data network of healthcare providers, pharmaceutical companies and contract research organizations used to enhance clinical trial design and accelerate patient recruitment. TriNetX enables researchers to find the right patients at the right sites for clinical trials. For more information, visit http://www.trinetx.com.
+1 (857) 285-6038
Logo - http://photos.prnewswire.com/prnh/20160303/340354LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/university-of-kentucky-joins-the-trinetx-network-to-revolutionize-clinical-trial-design-to-enhance-and-accelerate-the-development-of-new-drugs-300281068.html
SOURCE TriNetX, Inc.